Delving into the Latest Updates on Anti-CXCL13 HUmAb (JYANT Technologies) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

anti-CXCL13 HUmAb (JYANT Technologies)

Target

CXCL13

Mechanism

CXCL13 inhibitors(C-X-C motif chemokine 13 inhibitors)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication-

Inactive Indication

Castration-Resistant Prostatic Cancer

Originator Organization

Morehouse School of Medicine

Active Organization-

Inactive Organization

Morehouse School of Medicine

JYANT Technologies, Inc.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

OBJECTIVEThe aim of this study is to characterize antigenic sites on HIV-1 gp120 which may be important for the development of active and passive immunization strategies against HIV-1 infection.DESIGNTwo HIV-1-seropositive individuals were selected from the Amsterdam cohort and Epstein-Barr virus (EBV)-transformed B cells were generated from their peripheral blood mononuclear cells, which produce HIV-1-specific human monoclonal antibodies (HuMAb).METHODSHuMAb were generated and selected based on their reactivities with native gp120. Reactivity with HIV-1 strains from phylogenetically different subfamilies was determined by immunostaining and virus neutralization assays. Specificity for the CD4-binding site was tested by an inhibition enzyme-linked immunosorbent assay and amino acids (aa) involved in the binding of the HuMAb were identified with a set of gp120 molecules with single aa substitutions.RESULTSThree HuMAb (GP13, GP44, GP68) were generated, all recognizing a conserved conformation dependent epitope within, or topographically near, the CD4-binding site of gp120. HuMAb GP13 and GP68 neutralized a broad range of HIV-1 strains from phylogenetically different subfamilies, whereas HuMAb GP44 exhibited a more restricted pattern of neutralizing activity. The patterns of gp120 aa involved in their binding were unique for each of these HuMAb.CONCLUSIONSThe pattern of reactivities of these three HIV-1-neutralizing HuMAb developed in these studies is similar to, but distinct from other human and rodent MAb that recognize this antigenic site of HIV-1 gp120.

100 Deals associated with Anti-CXCL13 HUmAb (JYANT Technologies)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-Resistant Prostatic Cancer	Discovery	US	Morehouse School of Medicine	-
Castration-Resistant Prostatic Cancer	Discovery	US	JYANT Technologies, Inc.	-